

Rec Number	Name of Trial	Date Clock Started	Date of First Patient Recruited	Reasons for not achieving the 70 day benchmark										
				A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	
14/SC/0181	Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain	04/09/2014					Y							
14/EM/0034	A MULTICENTER, PHASE III, OPEN-LABEL, RANDOMIZED STUDY IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO EVALUATE THE BENEFIT OF GDC-0199 (ABT-199) PLUS RITUXIMAB COMPARED WITH BENDAMUSTINE PLUS RITUXIMAB	02/10/2014					Y							
13/LO/6758	The use of GnRH antagonist versus co-flare protocol for women with low ovarian reserve undergoing first cycle of in vitro fertilization	05/06/2014	14/04/2015				Y							
13/EE/0202	Intergroup Trial for Children or Adolescents with B-cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients.	05/12/2014					Y				Y			
14/EM/1071	Multicenter, open-label, randomised, pharmacokinetic (PK) and pharmacodynamic (PD) dose-ranging Phase II study of ticagrelor followed by a double-blind, randomised, parallel-group, placebo-controlled 4 weeks extension phase in paediatric patients with sickle cell disease	30/12/2014								Y				
14/LO/0818	A Randomized Open-Label Phase III Trial of MK-3475 versus Platinum based Chemotherapy in 1L Subjects with PD-L1 Strong Metastatic Non-Small Cell Lung Cancer	01/10/2014	16/06/2015				Y							
13/LO/1328	A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction.	15/01/2015								Y				
14/SW/1062	An Open-label, Phase 1b Study of ACP-196 in Subjects with Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma	13/02/2015								Y				
13/NE/0125	A prospective double blind randomised controlled study to evaluate the immunological benefits and clinical effects of an elimination diet using an amino acid formula (AAF) with an added pre-probiotic blend in infants with Cow's Milk Allergy (CMA)	16/02/2015								Y				
13/NW/0621	The early use of Antibiotics for at Risk Children with Influenza in primary care (ARCHIE): a double-blind randomised placebo-controlled trial	24/02/2015											Y	Y
14/WM/0057	Multi-centre randomised controlled trial to compare the clinical and cost-effectiveness of a 'vein bypass first' with a 'best endovascular first' revascularisation strategy for severe limb ischaemia due to infra-popliteal arterial disease: Bypass vs. Angioplasty in Severe Ischaemia of the Leg. The BASIL-2 trial	25/02/2015							Y					
12/NW/0827	International Randomised Controlled Trial for the Treatment of Newly Diagnosed Ewing's Sarcoma Family of Tumours	03/03/2015											Y	
14-LO-1786	RANDOMISED TRIAL OF HABIT TRAINING VS. HABIT TRAINING WITH DIRECT VISUAL BIOFEEDBACK IN ADULTS WITH CHRONIC CONSTIPATION	08/04/2015												Y
14/EM/1132	RCT to determine whether injection prior to Physiotherapy improves the outcome for large - Massive Rotator Cuff Tears: Which muscles are used to replace the Rotator Cuff in patients with good function and known large - Massive Cuff Tear, and does the location of the tear affect outcomes?	16/04/2015								Y				
14/EM/0209	An open label, intra-subject, controlled multi-centre study to assess the concordance (specificity and sensitivity) between Colourstart Test 73 mcg Cutaneous Patch and Finn Chamber in the detection of para-Phenylenediamine (PPD) allergy in subjects with known or clinically suspected allergy and those with no known allergy.	06/11/2014	20/04/2015							Y				
14/SC/1311	A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms	12/05/2015												Y
14/WM/1055	A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer	07/11/2014	10/03/2015							Y				
14/SC/1223	A phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.	08/06/2015								Y				

